487 related articles for article (PubMed ID: 29287214)
1. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
2. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
3. Brivaracetam augments short-term depression and slows vesicle recycling.
Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
[TBL] [Abstract][Full Text] [Related]
4. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
[TBL] [Abstract][Full Text] [Related]
5. Brivaracetam efficacy and safety in focal epilepsy.
Makke Y; Abou-Khalil B
Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
[No Abstract] [Full Text] [Related]
6. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
7. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
[TBL] [Abstract][Full Text] [Related]
8. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
[TBL] [Abstract][Full Text] [Related]
10. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
[TBL] [Abstract][Full Text] [Related]
11. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities.
Theochari E; Cock H; Lozsadi D; Galtrey C; Arevalo J; Mula M
Epilepsy Behav; 2019 Jan; 90():129-131. PubMed ID: 30530134
[TBL] [Abstract][Full Text] [Related]
12. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
14. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
Naddell S; Manuel M; Cavill R; White P; Sieradzan K
Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
17. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
[TBL] [Abstract][Full Text] [Related]
18. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
[TBL] [Abstract][Full Text] [Related]
19. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
[TBL] [Abstract][Full Text] [Related]
20. Brivaracetam for the treatment of epilepsy.
Schulze-Bonhage A
Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
